1-4 of 4
Marco Chinol
Close
Sort by
Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients

Anna Vanazzi, Chiara Grana, Daniele Laszlo, Marco Chinol, Mara Negri, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli
Journal: Blood
Blood (2012) 120 (21): 4876.
https://doi.org/10.1182/blood.V120.21.4876.4876
Published: 2012
Journal Articles

Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma

Anna Vanazzi, Pier Francesco Ferrucci, Chiara Maria Grana, Giancarlo Pruneri, Cristiano Crosta, Antonello Pinto, Marco Chinol, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli
Journal: Blood
Blood (2008) 112 (11): 3063.
https://doi.org/10.1182/blood.V112.11.3063.3063
Published: 2008
Journal Articles

Efficacy of 90Y-Ibritumomab Tiuxetan in Marginal-Zone Lymphoma (MZL).

Anna Vanazzi, MD, Pier Francesco Ferrucci, MD, Chiara Grana, MD, Giancarlo Pruneri, MD, Cristiano Crosta, MD, Antonello Pinto, MD, Marco Chinol, PhD, Giovanni Paganelli, MD, Giovanni Martinelli, MD
Journal: Blood
Blood (2007) 110 (11): 4499.
https://doi.org/10.1182/blood.V110.11.4499.4499
Published: 2007
Journal Articles

Efficacy of 90 Y-Ibritumomab Tiuxetan (Zevalin) in Refractory or Relapsed MALT Gastric Non Hodgkin’s Lymphoma.

Anna Vanazzi, MD, Pier F. Ferrucci, MD, Chiara Grana, MD, Giancarlo Pruneri, MD, Cristiano Crosta, MD, Antonello Pinto, MD, Marco Chinol, Giovanni Paganelli, MD, Giovanni Martinelli, MD
Journal: Blood
Blood (2006) 108 (11): 2771.
https://doi.org/10.1182/blood.V108.11.2771.2771
Published: 2006